Population-based analysis of ten-year outcomes with guideline-concordant management for triple-negative breast cancer

Analysis of data from the Centers for Disease Control and Prevention National Program of Cancer Registries investigated ten-year survival outcomes with guideline-concordant (GC) therapy versus non-GC therapy among women diagnosed with nonmetastatic triple-negative breast cancer (TNBC). The authors constructed a cohort of women diagnosed with stage I-III TNBC in 2004 (n=747) followed through 2015. Controlling for patient, tumor, and sociodemographic factors, patients whose management was GC had significantly better all-cause survival (HR 0.59; 95% CI 0.45-0.77), breast cancer-specific survival (0.60; 0.42-0.86), and non-breast cancer survival (0.63; 0.40-1.00) compared with those whose management was not GC. Treatment at a Commission on Cancer-accredited facility was a significant predictor of receiving GC care (OR 1.87; 95% CI 1.34-2.59). The authors conclude that additional population-based studies are urgently needed as new therapeutic approaches are being integrated into guidelines and clinical practice.